Possible long term teratogenic effect of isotretinoin in pregnancy

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue 5, 2009, Pages 393-396

  Malvasi, A ^b   Tinelli, Andrea ^a   Buia, A ^a   De Luca, G F ^a  

^a VITO FAZZI HOSPITAL   (Italy)

^b Santa Maria Hospital   (Italy)

Author keywords

Acne; Conjoined twins; Foetal malformations; Isotretinoin; Teratogenicity

Indexed keywords

ISOTRETINOIN;

ACNE; ADULT; ARTICLE; CASE REPORT; CONJOINED TWINS; DEPRESSION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FETUS MALFORMATION; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; LABOR INDUCTION; NULLIPARA; PREGNANCY; PREGNANT WOMAN; TERATOGENESIS; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ABNORMALITIES, DRUG-INDUCED; ACNE VULGARIS; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; PREGNANCY; PREGNANCY COMPLICATIONS; TERATOGENS; TIME FACTORS; TWINS, CONJOINED;

EID: 70450204582     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. THIBOUTOT DM, STRAUSS JS. Diseases of the sebaceous glands. In: Freedberg IM, Eisen AZ, Wolff K et al., eds. Fitzpatrick's Dermatology in General Medicine, 6th edn. McGraw-Hill, New York, 2003: pp 672-687.
2. WEBSTER GF. Acne vulgaris. Br Med J 2002; 325: 475-479.
3. GUPTA AK, LYNDE CW, POULIN Y, SMITH K, LEWIS R, ZIP C, PHARMACY AND THERAPEUTICS COMMITTEE, CANADIAN DERMATOLOGY ASSOCIATION. Position statement for isotretinoin. J Cutan Med Surg 2007; 11: 123-124.
4. STASHOWER ME. Pregnancy rates associated with isotretinoin (Accutane) and the FDA. J Am Acad Dermatol 2003; 49: 1202-1203.
5. MOSKOP JC, SMITH ML, DE VILLE K. Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 1997; 8: 264-278. (Pubitemid 127712738)
6. MCCLANE J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol 2001; 45: S188194.
7. GIANNOULIS CH, PAPATHANASIOU K, TANTANASIS TH, VAITSI V, TZAFETTAS I. Isotretinoin (Ro-Accutane) teratogenesis. A case report. Clin Exp Obstet Gynecol 2005; 32: 78.
8. BÉRARD A, AZOULAY L, KOREN G, BLAIS L, PERREAULT S, ORAICHI D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205.
9. GARCIA-BOURNISSEN F, TSUR L, GOLDSTEIN LH, STAROSELSKY A, AVNER M, ASRAR F, BERKOVITCH M, STRAFACE G, KOREN G, DE SANTIS M. Fetal exposure to isotretinoin-an international problem. Reprod Toxicol 2008; 25: 124-128.
10. SLADDEN MJ, HARMAN KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol 2007; 143: 1187-1188.
11. ABROMS L, MAIBACH E, LYON-DANIEL K, FELDMAN SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006; 3: e483.
12. AZOULAY L, ORAICHI D, BÉRARD A. Patterns and utilization of isotretinoin from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006; 62: 667-674.
13. STONE JL GOODRICH JT. The craniopagus malformation: classification and implications for surgical separation. Brain 2006; 129: 1084-1095.
14. BOUCHER N, BEAULAC-BAILLARGEON L. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Can Fam Physician 2006; 52: 338-339.
15. CHEETHAM TC, WAGNER RA, CHIU G, DAY JM, YOSHINAGA MA, WONG L. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006; 55: 442-448.
16. FARMACOVIGILANZA, Bollettino d'informazione sui farmaci (BIF) 2008; XV(6): 263-266.